MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$45.02 USD
+1.96 (4.55%)
Updated Aug 8, 2024 03:52 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MLTX 45.02 +1.96(4.55%)
Will MLTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLTX
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
MLTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for MLTX
Barclays Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
Buy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial Stability
MoonLake Immunotherapeutics: A Strong Buy on Solid Financials and Promising Clinical Trials
MoonLake Immunotherapeutics (MLTX) Receives a Buy from TD Cowen
MoonLake Immunotherapeutics GAAP EPS of -$0.39